Format

Send to

Choose Destination
J Cyst Fibros. 2014 Jan;13(1):29-36. doi: 10.1016/j.jcf.2013.06.008. Epub 2013 Jul 23.

Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.

Author information

1
Vertex Pharmaceuticals Incorporated, 130 Waverly St, Cambridge, MA, United States; Vertex Pharmaceuticals Incorporated, 11010 Torreyana Road, San Diego, CA 92121, United States. Electronic address: fredrick_vangoor@sd.vrtx.com.
2
Vertex Pharmaceuticals Incorporated, 11010 Torreyana Road, San Diego, CA 92121, United States.

Abstract

BACKGROUND:

Ivacaftor (KALYDECO™, VX-770) is a CFTR potentiator that increased CFTR channel activity and improved lung function in patients age 6 years and older with CF who have the G551D-CFTR gating mutation. The aim of this in vitro study was to evaluate the effect of ivacaftor on mutant CFTR protein forms with defects in protein processing and/or channel function.

METHODS:

The effect of ivacaftor on CFTR function was tested in electrophysiological studies using a panel of Fischer rat thyroid (FRT) cells expressing 54 missense CFTR mutations that cause defects in the amount or function of CFTR at the cell surface.

RESULTS:

Ivacaftor potentiated multiple mutant CFTR protein forms that produce functional CFTR at the cell surface. These included mutant CFTR forms with mild defects in CFTR processing or mild defects in CFTR channel conductance.

CONCLUSIONS:

These in vitro data indicated that ivacaftor is a broad acting CFTR potentiator and could be used to help stratify patients with CF who have different CFTR genotypes for studies investigating the potential clinical benefit of ivacaftor.

KEYWORDS:

CFTR; Ivacaftor; Potentiator; VX-770

PMID:
23891399
DOI:
10.1016/j.jcf.2013.06.008
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center